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Highlights • Rational modifications on a zinc-ejecting anti-RSV scaffold. • Synthesis of novel analogues to explore antiviral SARs. • New inhibitors of RSV replication identified. • Molecular dynamics and molecular docking studies on the RSV M2-1 protein. 
 
Abstract 
Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract diseases in 
infants and young children, with potentially serious and fatal consequences associated with 
severe infections. Despite extensive research efforts invested in the identification of therapeutic 
measures, no vaccine is currently available, while treatment options are limited to ribavirin and 
palivizumab, which both present significant limitations. While clinical and pre-clinical 
candidates mainly target the viral fusion protein, the nucleocapsid protein or the viral 
polymerase, our focus has been the identification of new antiviral compounds targeting the 
viral M2-1 protein, thanks to the presence of a zinc-ejecting group in their chemical structure. 
Starting from an anti-RSV hit we had previously identified with an in silico structure-based 
approach, we have designed, synthesised and evaluated a new series of dithiocarbamate 
analogues, with which we have explored the antiviral activity of this scaffold. The findings 
presented in this work may provide the basis for the identification of a new antiviral lead to 
treat RSV infections. 
 
1. Introduction 
Respiratory syncytial virus (RSV), a paramyxovirus,1 is the major responsible for acute lower 
respiratory tract infections in infants, children, immunocompromised patients, and elderly 
populations.2 Severe infections with this virus are often culminating in bronchiolitis and 
pneumonia, with potentially fatal consequences:3 RSV is estimated to cause between 66000 
and 199000 deaths every year in children under the age of five.4 Despite the fact that  extensive 
research efforts have been dedicated to elucidate epidemiology, diagnosis and 
prevention/treatment since its discovery in 1956, no vaccine is currently available for this 
virus.5 Two antiviral drugs are approved by the FDA to treat or prevent serious RSV infections: 
ribavirin, a guanosine analogue with a broad-spectrum antiviral activity approved for treatment 
in aerosolic form,6 and palivizumab, a humanised monoclonal antibody with strong RSV-
neutralising ability, which can be used for prophylactic purposes.7 Nonetheless, ribavirin is 
non-specific for RSV, therefore not highly efficacious, and associated with toxicity issues and 
high costs,8 while the use of palivizumab is limited to high-risk populations due to its elevated 
cost.9 Different additional strategies to treat or prevent RSV infections are currently under 
clinical evaluation, including recombinant antibodies, nanobodies and small molecules 
targeting the viral life cycle.10 The most explored mechanism of action with small-molecule 
antiviral candidates is the inhibition of RSV fusion, which accounts for different agents in 
phase II clinical trials.11 Other candidates in clinical development include inhibitors of the viral 
nucleoprotein and inhibitors of the viral polymerase, which accounts for one nucleoside 
analogue, ALS-008176, in clinical evaluation, and various nucleoside and non-nucleoside 
inhibitors currently at different stages of pre-clinical investigations.10-11 Despite these 
advances, the development of safe and effective treatment options for RSV infections still 
represents an unmet medical need. 
RSV is classified into two main groups, RSV-A and RSV-B, according to the antigenic 
sequence of the viral attachment glycoprotein, the G protein.12 Among the proteins encoded in 
RSV non-segmented, single-stranded, negative-sense RNA genome, the matrix protein M2-1 
is an essential transcription anti-termination co-factor of the viral polymerase,13 and currently 
represents an underexploited target in the search for anti-RSV agents, with no candidate in pre-
clinical or clinical development. The M2-1 protein is functional in a tetrameric form,14 and 
contains a zinc-binding domain (ZBD), whose proper functionality in coordinating a zinc ion 
co-factor is crucial for the enzyme activity.15 The zinc-binding activity of the M2-1 protein has 
been proven essential for viral replication and pathogenesis in vivo for related pneumoviruses,16 
rendering its inhibition a promising strategy for developing new antivirals against RSV. In this 
context, one appealing approach to inhibit zinc-binding enzymes is represented by metal 
chelation with zinc-ejecting compounds, as is the case for example of zinc-ejecting HIV 
nucleocapsid inhibitors, some of which have reached phase II clinical trials for the treatment 
of AIDS.17 Starting from the identification of zinc-chelating small-molecule aldrithiol, AT-2, 
as inactivator of RSV at millimolar concentrations,18 and thanks to the availability of crystal 
structures of RSV M2-1 protein complexes,19-20 we have previously applied a structure-based 
drug design approach to this protein, which guided the synthesis of different new structural 
scaffolds.21 These novel small-molecules were characterised by the presence of a central zinc-
ejecting chemical group, functionalised with different lateral substituents to interact with the 
protein sub-sites surrounding the ZBD. Among these structures, we had identified a new 
dithiocarbamate scaffold (compound 1 in Figure 1), which inhibited RSV replication in vitro 
with an EC50 in the low micromolar range, without causing significant cytotoxicity. Aiming at 
further exploring the anti-RSV activity of this compound, the present study focusses on the 
design, synthesis and evaluation of a preliminary series of structural derivatives of 1. Herein 
we describe the identification of new potential anti-RSV agents with antiviral EC50 values in 
the low micromolar range, and the evaluation of their predicted binding to RSV M2-1 protein 
with a series of molecular dynamics and molecular docking simulations. 
 
 
Figure 1: Chemical structure of aldrithiol (AT-2) and hit 1. 
 
2. Results and Discussion 
In this manuscript, in an effort to further improve the RSV replication inhibitory activity and 
to study the structure-activity relationships with new derivatives of our initial hit 1, we focussed 
our attention on introducing various electron-donating (EDG)/ electron-withdrawing (EWG) 
groups at different positions of the phenyl ring, and on replacing the original methylene bridge 
between the piperazine central core and the phenyl ring itself (Figure 2). The dithiocarbamate 
group, which is fundamental for its zinc-ejecting properties, the piperazine ring and the 
benzothiazole system, which in our pervious work were both found to be essential for the 
antiviral activity of 1, were kept unchanged, while their additional structural modifications is 
the focus of present investigations. 
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 Figure 2: Planned structural modifications on the scaffold of hit 1. 
 
 
 
2.1 Chemistry  
 
The newly designed derivatives were prepared following Scheme 1, which has been obtained 
after several optimisations of reactions and routes. 2-Chloromethyl benzothiazole (5) was 
prepared in two steps modifying a previously reported procedure for the preparation of 
benzothiazinone compounds, by reacting 2-aminothiophenol (2) with chloroacetic acid (3), in 
dichloromethane (DCM) for 24 h, in the absence of any base. 22, 23 The isolated amide salt 4 
was then cyclised in acetonitrile (CH3CN) at reflux for 72 h, giving the desired product in a 
better yield in comparison to a one-step synthesis method performed in parallel, in which 
intermediate amid salt 4 was the major product, with the desired compound obtained in a very 
low yield (6 %).24 Benzyl piperazine derivatives (22-36) were obtained in good yields by 
reacting the corresponding commercially available benzyl chloride (7-21) with a large excess 
of piperazine (6), in order to avoid a double nucleophilic attack and the formation of a di-
substituted piperazine molecule.25,26,27 Piperazine derivatives (34-36), in which the methylene 
linker has been replaced, were prepared exploiting  different reagents and conditions in order 
to obtain the desired product in a good yield after column chromatography purification.25,28,29 
Phenyl-piperazine 37 was purchased. Preparation of the final dithiocarbamate compounds 38-
46 was achieved through a nucleophilic displacement according to a reported one-step 
reaction,30 in which benzyl piperazine derivatives (22-30) and carbon disulfide were reacted in 
dimethylformamide (DMF), in the presence of sodium methoxyde (NaOMe) at 0 ˚C, followed 
by the addition of 5 to give the desired product. Final compounds 47-53 were obtained 
following a different two-step reaction, in which piperazine derivatives 31-37 and a large 
excess of carbon disulfide were reacted for 2 h in a strong basic ethanolic solution of potassium 
hydroxide (KOH), forming dithiocarbamate salts 31a-37a.31,32 The salts, recovered by 
filtration, were then reacted with 5 for 24 h using methanol (MeOH) as solvent and 
triethylamine (Et3N) as base, to afford the final products 47-53. Although both methods 
produced a similar range of final yields, the use of EtOH or MeOH as solvent instead of DMF 
and the absence of formation of side products, which makes the reaction purification much 
easier, suggested that the 2-step reaction was the most efficient procedure to follow.   
 
 
Scheme 1: Reagents and conditions: (i). DCM, r.t.,24h; (ii). CH3CN, reflux, 72h, 59%; (iii). THF, reflux, 4h for 22-33, 49-
88%, OR THF, reflux, 48h for 34, 72%, OR DCM, 0˚C, 30 min. for 35, 84%, OR EtOH, r.t., 5h for 36, 75%; (iv). CS2, NaOMe, 
DMF 0˚C 30 min, then o.n. for 38-46, 38-76%; (v). a) CS2, KOH, EtOH 0˚C then r.t., 2h; b) Et3N, MeOH, r.r., 24h for 47-53, 
40-56%.  
 
 
2.2 Antiviral evaluation 
 
All the newly synthetised compounds were evaluated for their potential antiviral activity in a 
cytophatic effect (CPE)-based in vitro assay in HEp-2 cells, in which the protective effect of 
the tested compounds against the virus-induced CPE was measured. Two different viral RSV 
strains, RSV-A and RSV-B, were used. Cells were treated with eight different concentrations 
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(0.7-100 µM) of the potential RSV inhibitors. The nucleoside viral polymerase inhibitor ALS-
8112 was used as positive control.33 
Compound cytotoxicity (CC50) was also determined using uninfected HEp-2 cells in a MTS 
assay. Results are reported in Table 1. 
The activity of initial hit 1 is consistent with previously reported data,21 showing an antiviral 
effect in the low µM range against both viral strains. Insertion of an electron donating 
substituent in the para position of the phenyl ring, such as a mehtoxy (38), methyl (41) and t-
butyl (39) group, seems to be associated with antiviral activity retention against strain B-RSV, 
having EC50 values similar to 1. On the contrary, these compounds show a different effect 
against strain A, giving a slightly less potent and more variable activity profile. The same effect 
against strain B is obtained when electron withdrawing groups, such as a methyl (40), a ethyl-
carboxylic ester (46), a trifluoromethyl (49) and a fluorine (47) in the para position. Notably, 
while 40 and 46 are characterised by a reduction of antiviral effect against strain A, derivatives 
47 and 49 present similar EC50 values against both strains. In general, these results indicate that 
the para position of the phenyl ring can be substituted without affecting antiviral activity. 
Importantly, the possibility to insert a fluorine atom or a trifluoromethyl group into the phenyl 
ring without impairing the biological activity could be used as means to exploit the established 
potential of fluorine atoms in enhancing the pharmacological profile and drug-like 
physicochemical properties of molecules with pharmacological activities, for the potential 
future development of this class of compounds.34 The presence of a substituent in meta position 
of the phenyl ring (45, 48), regardless its EDG/EWG nature, is associated with a retained 
antiviral effect, with 48 having an equivalent EC50 value against strain A and B, while the 
introduction of a methyl group in ortho (44) is correlated with a reduction of activity, indicating 
that there is enough space on the binding pocket to accommodate a phenyl ring differently 
substituted in meta or in para position, but not in  ortho position. 
Introduction of a second methyl group at the ortho position of 41 (42) is associated with a 
reduction of activity against strain B, while it seems not to affect antiviral activity against strain 
A. A more consistent result against the two strains is obtained inserting a third methyl group 
in ortho (43), which is associated with an almost 5-fold reduction in activity in both cases.  
Extension of the methylene bridge to an ethyl linker (50) or its replacement with a -SO2- (51) 
slightly affects antiviral activity, whereas a -CO- (52) linker led to a more marked drop of 
activity against the two strains. The reduction in activity could be either caused by the different 
polarity of the new linker, or by the different geometry conferred to the molecule. Interestingly, 
53, in which the terminal phenyl ring is directly connected to the piperazine core, showed an 
improved antiviral activity, revealing to be the best compound in this series, with an interesting 
antiviral profile against both viral strains. 
All the evaluated molecules, except 39 and 52, were found not to be cytotoxic at the test 
concentrations in uninfected HEp-2 cells.   
Table 1: EC50 and CC50 values of 1, 39-53 in the RSV CPE reduction assay. 
 
Compound Structure 
 
 
EC50 values 
[μM]A,B
 
EC50 values 
[μM]A,C 
CC50 values 
[μM]D 
1 -CH2Ph 8.3C 3.9±0.1 >100 
38 -CH2(4-OCH3-Ph) 12.9±13.8 3.0±1.4 >100 
39 -CH2(4-C(CH3)3-Ph) 28.7±29.0 2.2±1.5 71.7±27.3 
40 -CH2(4-COOCH3-Ph) 14.8±9.0 3.9±0.1 >100 
41 -CH2(4-CH3-Ph) 17.9±19.6 1.32 >100 
42 -CH2(2,4-CH3-Ph) 4.97 15.0±19.2 >100 
43 -CH2(2,4,6-CH3-Ph) 42.2±40.7 20.6 >100 
44 -CH2(2-CH3-Ph) 10.4±3.2 20.6 >100 
45 -CH2(3-CH3-Ph) 11.8±8.9 3.0±1.5 >100 
46 -CH2(4-COOCH2CH3-Ph) 40.8±13.3 4.0±0.1 >100 
47 -CH2(4-F-Ph) 4.4±1.9 2.5 >100 
48 -CH2(3-CF3-Ph) 3.3±0.1 3.8±0.1 >100 
49 -CH2(4-CF3-Ph) 3.31 4.7±6.7 >100 
50 - CH2CH2Ph 7.7±5.0 13.6±18.9 >100 
51 -SO2Ph 35.3±15.2 12.5±1.2 >100 
52 -COPh 44.1±15.2 24.8 45.0±30.8 
53 -Ph 4.4±1.1 1.3±0.2 >100 
ALS-8112 - 2.6±1.5 2.6±1.5 >100 
A
 EC50 and CC50 values are the mean of at least 2 independent experiments, with standard 
deviations of ±10% of the value quoted unless otherwise stated (mean value ± standard 
deviations). CPE scoring in RSV/Hep2 cell culture system. ALS-8112 was used as positive 
control.  
N
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B
 RSV-A strain 
C
 RSV-B strain 
D Toxicity in Hep2 cell using viability staining with MTS. 
E EC50 previously determined= 6 µM.21 
 
2.3 Molecular modelling studies 
In order to identify a likely binding mode for the new derivatives to the M2-1 protein and 
rationalise the biological results obtained, a series of docking studies was performed on 
selected compounds (1, 43, 48, 52, 53). The recently reported M2-1 protein complex crystal 
structure (PDB ID: 6G0Y) was used, and docking studies were performed using Glide SP 
scoring function.20,35 Compound 1 is predicted to lie in a large pocket formed by three 
monomers immediately above the zinc-binding domain (ZBD) of one of them (Figure 3A). 
The benzothiazole ring occupies the entrance of the binding site with its sulphur atom oriented 
towards the oxygen atom of the GlyA18 backbone and it is involved in a π-interaction with 
LysB113. The unsubstituted benzyl ring is placed in the inner portion of the pocket, involved 
in a sandwich π-stacking interaction with HisA14, which probably holds in place this part of 
the molecule. The central piperazine ring establishes multiple interactions with AspB109, 
which locks 1 in a conformation that allows the sulphur atom of the thiocarbamate moiety to 
be oriented towards the Zn-binding domain. Moreover, the piperazine ring interacts with 
Cys15A, one of the three cysteine residues involved in the coordination of the Zn atom. A 
similar occupation of the pocket and interactions were found for 48 (Figure 3B), with the only 
difference in the benzyl ring positioning. In fact, the m-CF3 group, potentially due to steric 
hindrance, forces the ring to occupy the pocket in a different position, with the sulphur atom 
remaining close to the Zn-binding domain. Moreover, the piperazine ring forms a π-interaction 
with HisA25, another residue involved in the Zn atom coordination. The shorter derivative 53 
occupies the binding cavity similarly to 48 (Figure 3C). Interestingly, no docking results were 
obtained for derivative 43. Potentially, the tri-substituted benzyl ring, due to steric hindrance, 
does not fit into the inner part of the binding area, not allowing the rest of the molecule to 
correctly bind to the active site, possibly explaining the large reduction in antiviral activity 
found for this compound.  
On the other hand, compound 52 occupies the pocket in a different orientation if compared 
with the other active derivatives, placing the carbonyl group in correspondence of the Zn- 
binding area, driven by its interaction with the backbone of GlyA18, therefore forcing the 
thiocarbamate moiety to point away from this area, impeding its interaction with the Zn atom 
and the surrounding residues (Figure 3D).  
 
Figure 3: Proposed binding mode for compounds 1 (A), 48 (B), 53 (C), 52 (D) in the ZBD of 
the M2-1 protein (PDB ID: 6G0Y). Compounds bind in a large pocket formed by three 
monomers immediately above the zinc-binding domain (ZBD) of one of them. Importantly, the 
sulphur atom of the thiocarbamate moiety is always oriented towards the ZBD except for 52. 
The single monomers of M2-1 protein forming the functional tetramers are represented as 
molecular surface and ribbons: monomer A in salmon, monomer B in turquoise, monomer C 
in blue, monomer D in yellow. The residues of the different monomers are coloured 
accordingly. Carbon atoms of compound 1 are shown in purple, in orange for 48, in pink for 
53 and in green for 52. The ZBD of monomer A is labelled. 
 
In order to validate the suggested binding mode, a series of 150 ns molecular dynamics (MD) 
simulations on 1, 48 and 53 were performed, using the Desmond software package for MD 
simulations.36 All the protein-ligand systems reached stability after an initial 70 ns of 
equilibration, as showed by the C-alpha RMSD variation, therefore only the remaining 80 ns 
of the simulation were considered in our analysis (Figure 4).  
 
 
 
 Figure 4: Plots of RMSD (Å) values against simulation frames for protein-inhibitor 
complexes. After 70 ns of equilibration (red dotted line, corresponding to frame 1750), the 
proteins reach stability (C-alpha RMSD variation). Only one replicate is shown for each 
different protein-ligand complex. Color legend: 1-protein (purple), 48-protein (orange), 53-
protein (pink), 52-protein (green). 
 
In general, all the three molecules tend to optimise their occupation of the binding site 
maintaining then a stable pose during the entire MD simulation, with the thiocarbamate moiety 
always oriented and placed nearby the Zn-binding domain. (Figure 5A, example of compound 
1). In particular, the initial ligand-protein interactions with HisA14 (hydrophobic interactions) 
and LysB113 (alternation between hydrophobic interaction and water bridges) are maintained 
for most of the MD simulation (Figure 5B). The initial interactions between the piperazine 
ring and AspB109 are then mediated by a water bridge, whereas an extra interaction between 
the benzothiazole ring of all the tree derivatives and residue TyrC72 is formed (either as 
hydrophobic contact or water bridge) and maintained during the entire simulation, potentially 
contributing to the protein-ligand complex stability. As negative control, a MD simulation for 
52 was also performed. The starting binding pose was maintained for the entire simulation, 
with the thiocarbamate moiety always pointing away from the Zn-binding domain.  
 
 Figure 5: A) Proposed binding mode for 1 at the beginning of the MD simulation and after 
150 ns. 1 tends to optimise its occupation of the binding site with the thiocarbamate moiety 
always oriented and placed nearby the Zn-binding domain.  Carbon atoms of 1 are shown in 
purple, molecules of water as red spheres. The final pose shown is from the last frame of only 
one replicate of the MD simulation for the 1-protein complex. B) Compound 1-protein contacts 
monitored throughout the MD simulation. The stacked bar charts are normalised by the 
program over the course of the trajectory: a value of 0.8 suggests that a specific interaction is 
maintained for 80% of the simulation time. Only the simulation time between 80 ns and 150 
ns (after equilibration of the system as discussed above) was considered in our analysis. The 
analysis of only one MD replicate is shown. 
 
To confirm the stability of these protein-ligand complexes, the compounds relative binding 
free energies (∆Gbinding) were then calculated using the Prime/MM-GBSA based calculation 
method for 1, 48 and 53.37,38 According to the ∆Gbinding values obtained, the three ligand-protein 
complexes show similar results, in line with the similar biological activities found for these 
three molecules (Table 2). In conclusion, molecular docking and MD studies have given 
important elucidations on the potential binding mode for this family of compounds. The 
information thus obtained will be used to perform further structural modifications on the 
current scaffold.  
 
Table 2: Calculated ligand-interaction energies for the compounds analysed after the  
molecular dynamics simulations. 
Compound ∆Gbinding (kJ/mol)a ±SD 
1 -47.40±6.39 
48 -42.80±8.40 
53 -43.07±4.45 
 
a Average values calculated as mean of three of ΔGbinding obtained from three indipendent MD 
simulations (triplicate) for each compound. For each replicate, the average ΔGbinding value was 
calculated excluding the first 70 ns of MD, in which the system protein-ligand reached stability. 
Standard deviation (SD) is reported. 
 
3. Conclusions 
Starting from an anti-RSV hit we had previously identified with an in silico structure-based 
approach and applying standard medicinal chemistry modifications, a family of 16 new 
derivatives has been designed and synthesised.  All newly prepared compounds were evaluated 
for their potential antiviral activity in a cytophatic effect (CPE)-based in vitro assay in HEp-2 
cells, using two different RSV strains, RSV-A and RSV-B. Among them, different displayed 
retained activity, including the original hit 1, with no cytotoxic associated, confirming the anti-
RSV profile associated with this new scaffold. Most interestingly, 53, in which the terminal 
phenyl ring is directly connected to the piperazine core, was found as the best compound in 
this series, with an interesting antiviral profile against both viral strains, with EC50 values in 
the low µM range. Molecular modelling studies revealed important information on the potential 
binding mode of this family of compounds to their putative target, the viral M2-1 protein. 
In conclusion, the antiviral activity associated with this chemical scaffold has been confirmed 
and the phenyl derivative 53 was found to be an effective anti-RSV inhibitor with no toxicity 
associated. The biological and in silico results obtained represent a promising starting point for 
further structure-activity relationship enhancement, in order to improve potency in the quest 
for an effective antiviral treatment for human RSV infections. 
   
 
4. Experimental section 
4.1 General Chemistry methods, general procedures and compound 
characterisation examples 
All solvents and reagents were used as obtained from commercial sources unless otherwise 
indicated. All solvents used for chromatography were HPLC grade from Fisher Scientific 
(UK). All reactions were performed under a nitrogen atmosphere. 1H and 13C-NMR spectra 
were recorded with a Bruker Avance III HD spectrometer operating at 500 MHz for 1H and 
125 MHz for 13C, with Me4Si as internal standard. Deuterated chloroform was used as the 
solvent for NMR experiments, unless otherwise stated. 1H chemical shifts values (δ) are 
referenced to the residual non-deuterated components of the NMR solvents (δ = 7.26 ppm for 
CHCl3, etc.). The 13C chemical shifts (δ) are referenced to CDCl3 (central peak, δ = 77.0 ppm). 
TLC was performed on silica gel 60 F254 plastic sheets. Flash column chromatography was 
performed using silica on an Biotage Isolera 1 system. Melting points were determined on an 
electro-thermal instrument, Griffin apparatus and are uncorrected. UPLC-MS analysis was 
conducted on a Waters UPLC system with both Diode Array detection and Electrospray (+’ve 
and –‘ve ion) MS detection. The stationary phase was a Waters Acquity UPLC BEH C18 1.7um 
2.1x50mm column. The mobile phase was LC-MS grade H2O containing 0.1% formic acid (A) 
and LC-MS grade MeCN containing 0.1% formic acid (B). Column temperature: 40 °C. 
Sample diluent: MeCN. Sample concentration 1µg/mL. Injection volume 2 µL. Three 
alternative methods were used: 
Linear gradient standard method (A): 90% A (0.1 min), 90%-0% A (2.5 min), 0% A (0.3 min), 
90% A (0.1 min); flow rate 0.5 mL/min. 
Linear gradient standard method (B): 90% A (0.1 min), 90%-0% A (2.1 min), 0% A (0.8 min), 
90% A (0.1 min); flow rate 0.5 mL/min. 
Linear gradient standard method (C): 90% A (0.1 min), 90%-0% A (1.5 min), 0% A (1.4 min), 
90% A (0.1 min); flow rate 0.5 mL/min. 
All compounds tested in biological assays were >95% pure. Purity of intermediates was >90%, 
unless otherwise stated. All intermediates were generally prepared according to literature 
procedures, which are described in detail along with compound characterisation in the 
Supporting Information. Details for the preparation and full characterisation of the new target 
final compounds are given below. 
 
4.1.1 General method A for the preparation of final compounds 38-46 
 
To a solution of substituted benzyl-piperazine (2 mmol) in dimethylformamide (5 mL) was 
added carbon disulphide (2 mmol) and sodium methoxide at 0 °C and it was stirred for 30 min. 
2-Chloromethyl benzothiazole (5)  (1 mmol) was added in one portion, the reaction mixture 
was left to reach room temperature and stirring was continued until the reaction was complete 
(monitoring by TLC). The reaction mixture was quenched by addition of ice-cold water and 
then it was extracted with EtOAc (25 mL), dried over MgSO4 and evaporated to give the crude 
product. Purification by flash column chromatography (n-hexane:EtOAc 100:0 v/v, increasing 
to 80:20 v/v) gave the pure product. 
 
4.1.2 Benzo[d]thiazol-2-ylmethyl 4-(4-methoxybenzyl)piperazine-1-carbodithioate (38) 
Obtained in 75% yield as a white solid. 1H-NMR (CDCl3) δ: 2.52 (bs, 4H, CH2-piperazine), 
3.48 (s, 2H, CH2), 3.78 (s, 3H, -OCH3), 3.93 (bs, 2H, CH2-piperazine), 4.35 (bs, 2H, CH2-
piperazine), 5.11 (s, 2H, CH2), 6.79 (d, J= 8.6 Hz, 2H, H-aromatic), 7.14 (d, J= 8.6 Hz, 2H, H-
aromatic), 7.35-7.38 (m, 1H, H-aromatic), 7.44-7.47 (m, 1H, H-aromatic), 7.81-7.84 (m, 1H, 
H-aromatic), 7.97-8.00 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 38.9 (CH2), 52.2 (CH2), 
55.2 (CH3), 61.8 (CH2), 113.7, 121.6, 122.9, 125.2, 126.0, (CH, C-aromatic), 129.2 (C), 130.3 
(CH, C-aromatic), 135.7, 152.7, 159.0, 167.7, 194.2 (C). Melting point: 81-83° C. UPLC-MS 
(Method C): Rt 1.67 min, MS [ESI, m/z]: 430.2 [M+H]. Anal. Calcd for C21H23N3OS3: C, 
58.71; H, 5.40; N, 9.78. Found: C, 58.86; H, 5.20; N, 9.71. 
4.1.3 Benzo[d]thiazol-2-ylmethyl4-(4-(tert-butyl)benzyl) piperazine-1-carbodithioate (39) 
Obtained in 69% yield as a yellow waxy solid. 1H-NMR (CDCl3) δ: 1.31 (s, 9H, CH3 tert-
butyl), 2.54 (bs, 4H, CH2-piperazine), 3.51 (s, 2H, CH2), 3.95 (bs, 2H, CH2-piperazine), 4.37 
(bs, 2H, CH2-piperazine), 5.11 (s, 2H, CH2), 7.23 (d, J= 8.3 Hz, 2H, H-aromatic), 7.33-7.38 
(m, 3H, H-aromatic), 7.44-7.47 (m, 1H, H-aromatic), 7.81-7.84 (m, 1H, H-aromatic), 7.97-8.00 
(m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 31.3 (CH3), 38.9 (CH2), 52.3 (CH2), 62.1 (CH2), 
68.1 (C), 121.6, 122.9, 125.2, 125.3, 126.0, 128.8 (CH, C-aromatic), 130.8, 135.7, 150.4, 152.7, 
167.7, 194.2 (C). Melting point: 73-75° C. UPLC-MS (Method C): Rt 1.89 min, MS [ESI, m/z]: 
456.2 [M+H]. Anal. Calcd for C24H29N3S3: C, 63.26; H, 6.41; N, 9.22. Found: C, 63.22; H, 
6.59; N, 9.05. 
4.1.4 Methyl4-((4-(((benzo[d]thiazol-2-ylmethyl) thio) carbonothioyl) piperazin-1-yl) 
methyl) benzoate (40) 
Obtained in 76% yield as a yellow solid. 1H-NMR (CDCl3) δ: 2.55 (bs, 4H, CH2-piperazine), 
3.58 (s, 2H, CH2), 3.91 (s, 3H, CH3 methyl ester), 3.95 (bs, 2H, CH2-piperazine), 4.37 (bs, 2H, 
CH2-piperazine), 5.11 (s, 2H, CH2), 7.41-7.35 (m, 3H, H-aromatic), 7.44-7.47 (m, 1H, H-
aromatic), 7.81-7.83 (m, 1H, H-aromatic), 7.97-8.01 (m, 3H, H-aromatic). 13C-NMR (CDCl3) 
δ: 39.0 (CH2), 51.9 (CH3), 52.4 (CH2), 62.0 (CH2), 121.6, 122.9, 125.2, 126.0, 128.8 (CH, C-
aromatic), 129.4 (C), 129.7 (CH, C-aromatic), 135.7, 142.7, 152.7, 166.9, 167.6, 194.4 (C). 
Melting point: 83-85° C. UPLC-MS (Method C): Rt 1.79 min, MS [ESI, m/z]: 458.2 [M+H]. 
Anal. Calcd for C22H23N3O2S3: C, 57.74; H, 5.07; N, 9.18. Found: C, 57.89; H, 4.88; N, 8.93. 
4.1.5 Benzo[d]thiazol-2-ylmethyl 4-(4-methylbenzyl)piperazine-1-carbodithioate (41) 
Obtained in 49% yield as a yellow solid. 1H-NMR (CDCl3) δ: 2.33 (s, 3H, CH3), 2.54 (bs, 4H, 
CH2-piperazine), 3.50 (s, 2H, CH2), 3.95 (bs, 2H, CH2-piperazine), 4.36 (bs, 2H, CH2-
piperazine), 5.12 (s, 2H, CH2), 7.16 (d, J= 7.8 Hz, 2H, H-aromatic), 7.21 (d, J= 7.8 Hz, 2H, H-
aromatic)7.35-7.38 (m, 1H, H-aromatic), 7.45-7.48 (m, 1H, H-aromatic), 7.82-7.84 (m, 1H, H-
aromatic), 7.97-7.99 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 21.1 (CH3), 38.9 (CH2), 52.3 
(CH2), 62.1 (CH2), 121.6, 122.9, 125.2, 126.0, 129.1, 129.1 (CH, C-aromatic), 135.7, 137.1, 
152.7, 159.1, 167.7, 194.2 (C). Melting point: 95-97° C. UPLC-MS (Method C): Rt 1.74 min, 
MS [ESI, m/z]: 414.2 [M+H]. Anal. Calcd for C21H23N3S3: C, 60.98; H, 5.61; N, 10.16. Found: 
C, 61.04; H, 5.34; N, 10.03. 
4.1.6 Benzo[d]thiazol-2-ylmethyl4-(2,4-dimethylbenzyl) piperazine-1-carbodithioate (42) 
Obtained in 38% yield as a yellow waxy solid. 1H-NMR (CDCl3): 2.30 (s, 3H, CH3), 2.33 (s, 
3H, CH3), 2.53 (bs, 4H, CH2-piperazine), 3.46 (s, 2H, CH2), 3.91 (bs, 2H, CH2-piperazine), 
4.34 (bs, 2H, CH2-piperazine), 5.11 (s, 2H, CH2), 6.95-7.00 (m, 2H, H-aromatic), 7.09 (d, J= 
7.5 Hz, 2H, H-aromatic), 7.35-7.38 (m, 1H, H-aromatic), 7.44-7.47 (m, 1H, H-aromatic), 7.81-
7.83 (m, 1H, H-aromatic), 7.97-7.99 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 19.1 (CH3), 
21.0 (CH3), 38.9 (CH2), 52.4 (CH2), 60.10(CH2), 121.6, 122.9, 125.23, 126.0, 126.2, 130.0, 
131.3 (CH, C-aromatic), 135.7, 137.4, 150.4, 152.7, 166.9, 167.7, 194.2 (C). Melting point: 
68-70° C. UPLC-MS (Method C): Rt 1.87 min, MS [ESI, m/z]: 428.2 [M+H]. Anal. Calcd for 
C22H25N3S3: C, 61.79; H, 5.89; N, 9.83. Found: C, 61.56; H, 6.07; N, 9.65. 
4.1.7 Benzo[d]thiazol-2-ylmethyl4-(2,4,6-trimethylbenzyl) piperazine-1-carbodithioate 
(43) 
Obtained in 68% yield as a yellow waxy solid. 1H-NMR (CDCl3): 2.26 (s, 3H, CH3), 2.33 (s, 
6H, CH3), 2.54 (bs, 4H, CH2-piperazine), 3.49 (s, 2H, CH2), 3.88 (bs, 2H, CH2-piperazine), 
4.31 (bs, 2H, CH2-piperazine), 5.29 (s, 2H, CH2), 6.84 (s, 2H, H-aromatic), 7.34-7.38 (m, 1H, 
H-aromatic), 7.44-7.47 (m, 1H, H-aromatic), 7.81-7.83 (m, 1H, H-aromatic), 7.97-7.99 (m, 1H, 
H-aromatic). 13C-NMR (CDCl3) δ: 20.0 (CH3), 20.9 (CH3), 38.9 (CH2), 52.0 (CH2), 55.2 (CH2), 
121.6,122.9, 125.2, 126.0, 129.0 (CH, C-aromatic), 130.8, 135.7, 136.8, 138.0, 152.7, 167.8, 
194.0 (C). Melting point: 82-84° C. UPLC-MS (Method C): Rt 2.10 min, MS [ESI, m/z]: 442.2 
[M+H]. Anal. Calcd for C23H27N3S3: C, 62.55; H, 6.16; N, 9.51. Found: C, 62.29; H, 6.01; N, 
9.75. 
4.1.8 Benzo[d]thiazol-2-ylmethyl 4-(2-methylbenzyl)piperazine-1-carbodithioate (44) 
Obtained in 72% yield as a light brown waxy solid. 1H-NMR (CDCl3): 2.37 (s, 3H, CH3), 2.54 
(bs, 4H, CH2-piperazine), 3.49 (s, 2H, CH2), 3.92 (bs, 2H, CH2-piperazine), 4.35 (bs, 2H, CH2-
piperazine), 5.12 (s, 2H, CH2), 7.13-7.23 (m, 4H, H-aromatic), 7.35-7.38 (m, 1H, H-aromatic), 
7.44-7.47 (m, 1H, H-aromatic), 7.81-7.83 (m, 1H, H-aromatic), 7.97-7.99 (m, 1H, H-aromatic). 
13C-NMR (CDCl3) δ: 19.2 (CH3), 38.9 (CH2), 52.4 (CH2), 60.36 (CH2), 121.6, 122.9, 125.2, 
125.6, 126.0, 127.5, 129.9, 130.4 (CH, C-aromatic), 135.7, 137.6, 152.7, 166.9, 167.7, 194.2 
(C). Melting point: 98-100° C. UPLC-MS (Method C): Rt 1.79 min, MS [ESI, m/z]: 414.2 
[M+H]. Anal. Calcd for C21H23N3S3: C, 60.98; H, 5.61; N, 10.16. Found: C, 61.16; H, 5.37; N, 
10.09. 
4.1.9 Benzo[d]thiazol-2-ylmethyl 4-(3-methylbenzyl)piperazine-1-carbodithioate (45) 
Obtained in 45% yield as a yellow waxy solid. 1H-NMR (CDCl3): 2.35 (s, 3H, CH3), 2.55 (bs, 
4H, CH2-piperazine), 3.51 (s, 2H, CH2), 3.96 (bs, 2H, CH2-piperazine), 4.36 (bs, 2H, CH2-
piperazine), 5.12 (s, 2H, CH2), 7.09-7.14 (m, 3H, H-aromatic), 7.20-7.23 (m, 1H, H-aromatic), 
7.35-7.38 (m, 1H, H-aromatic), 7.44-7.48 (m, 1H, H-aromatic), 7.82-7.84 (m, 1H, H-aromatic), 
7.98-8.00 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 21.3 (CH3), 39.0 (CH2), 52.2 (CH2), 62.3 
(CH2), 121.6, 122.9, 125.2, 126.0, 126.4, 128.4, 128.5, 130.0 (CH, C-aromatic), 135.7, 138.2, 
152.7, 167.6, 168.4 194.4 (C). Melting point: 48-50° C. UPLC-MS (Method C): Rt 1.75 min, 
MS [ESI, m/z]: 414.2 [M+H]. Anal. Calcd for C21H23N3S3: C, 60.98; H, 5.61; N, 10.16. Found: 
C, 61.09; H, 5.82; N, 10.02. 
4.1.10 Benzo[d]thiazol-2-ylmethyl4-(4-propionylbenzyl) piperazine-1-carbodithioate (46) 
Obtained in 43% yield as a light brown waxy solid. 1H-NMR (CDCl3): 1.39 (t, J=7.1, 3H, CH3), 
2.54 (bs, 4H, CH2-piperazine), 3.58 (s, 2H, CH2), 3.96 (bs, 2H, CH2-piperazine), 4.42-4.33 (m, 
4H, CH2 piperazine and CH2 ethyl ester), 5.10 (s, 2H, CH2), 7.35-7.39 (m, 1H, H-aromatic), 
7.40 (d, J= 8.2 Hz, 2H, H-aromatic), 7.44-7.47 (m, 1H, H-aromatic), 7.81-7.83 (m, 1H, H-
aromatic), 7.97-8.00 (m, 1H, H-aromatic), 8.01 (d, J= 8.2 Hz, 2H, H-aromatic). 13C-NMR 
(CDCl3) δ: 14.3 (CH3), 39.0 (CH2), 52.4 (CH2), 60.98 (CH2), 62.03 (CH2), 121.6, 122.9, 125.2, 
126.0, 128.9, 129.7 (CH, C-aromatic), 133.9, 135.7, 138.2, 152.7, 166.4, 167.6, 194.5 (C). 
Melting point: 70-72° C. UPLC-MS (Method C): Rt 1.89min, MS [ESI, m/z]: 472.1 [M+H]. 
Anal. Calcd for C23H25N3O2S3: C, 58.57; H, 5.34; N, 8.91. Found: C, 58.34; H, 5.19; N, 9.14. 
 
4.1.11 General method B for the preparation of final compounds 47-53 
 
To an ethanolic solution of potassium hydroxide (1mmol/100mL) a secondary amine (1 mmol) 
was added. The mixture was cooled in an ice-bath and carbon disulphide (10 mmol) was added 
drop-wise while stirring. The reaction mixture was stirred for 2 h at room temperature and then 
the solvent volume was reduced by evaporation under reduced pressure. Addition of diethyl 
ether until precipitation reached completion and filtration afforded the solid intermediate salt. 
To a mixture of salt (1 mmol), methanol (5mL) and triethylamine (1.5 mmol) was added 2- 
chloromethyl benzothiazole (5) (1mmol) and the reaction mixture was stirred at room 
temperature for 24 h. The methanol from the reaction mixture was evaporated under reduce 
pressure, EtOAc was added and the resulting solid was filtered off. The filtrate was washed 
with H2O (3x15mL). The organic layers were collected, dried over MgSO4 and concentrated 
under reduce pressure to give the crude product. Purification by flash column chromatography 
gave the pure product. 
4.1.12 Benzo[d]thiazol-2-ylmethyl 4-(4-fluorobenzyl)piperazine-1-carbodithioate (47) 
Obtained in 45% yield as a yellow solid. Purification by flash column chromatography 
(DCM:MeOH 100:0 v/v, increasing to 90:10 v/v). 1H-NMR (CDCl3): 2.47-2.60 (m, 4H, CH2-
piperazine), 3.49 (s, 2H, CH2), 3.94 (bs, 2H, CH2-piperazine), 4.37 (bs, 2H, CH2 piperazine), 
5.11 (s, 2H, CH2), 7.00-7.04 (m, 2H, H-aromatic), 7.27-7.30 (m, 2H, H-aromatic), 7.34-7.41 
(m, 1H, H-aromatic), 7.43-7.49 (m, 1H, H-aromatic), 7.80-7.86 (m, 1H, H-aromatic), 7.96-8.02 
(m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 39.0 (CH2), 52.2 (CH2), 61.6 (CH2), 115.3 (CH, d, 
J = 21 Hz), 121.6,122.9, 125.2, 125.8 (CH, C-aromatic), 130.6 (CH, d, J= 7 Hz), 135.7, 152.7, 
161.2, 163.2, 167.7, 194.4 (C). 19F-NMR (CDCl3) δ: -115.15 (s, 1F). Melting point: 77-79° C. 
UPLC-MS (Method C): Rt 1.75 min, MS [ESI, m/z]: 418.2 [M+H]. Anal. Calcd for 
C20H20FN3S3: C, 57.53; H, 4.83; N, 10.06. Found: C, 57.60; H, 4.68; N, 9.92. 
4.1.13 Benzo[d]thiazol-2-ylmethyl4-(3-(trifluoromethyl)benzyl) piperazine-1-
carbodithioate (48) 
Obtained in 54% yield as a yellow solid. Purification by flash column chromatography 
(DCM:MeOH 100:0 v/v, increasing to 90:10 v/v). 1H-NMR (CDCl3): 2.55 (bs, 4H, CH2-
piperazine), 3.58 (s, 2H, CH2), 3.97 (bs, 2H, CH2-piperazine), 4.38 (m, 2H, CH2 piperazine), 
5.11 (s, 2H, CH2), 7.35-7.38 (m, 1H, H-aromatic), 7.44-7.48 (m, 2H, H-aromatic),7.51-7.55 
(m, 2H, H-aromatic), 7.59 (s, 1H, H-aromatic), 7.81-7.83 (m, 1H, H-aromatic), 7.97-7.99 (m, 
1H, H-aromatic). 13C-NMR (CDCl3) δ: 39.0 (CH2), 52.4 (CH2), 61.8 (CH2,), 121.6, 122.9, 
124.4 (m), 125.2, 125.6 (m), 126.0, 128.9, 132.3 (CH), 123.1 (m), 130.7 (C, q, J= 33 Hz), 
135.7, 152.7, 161.2, 167.6, 194.5 (C). 19F-NMR (CDCl3) δ: -62.55 (s, 3F). Melting point: 71-
73°C. UPLC-MS (Method C): Rt 2.02 min, MS [ESI, m/z]: 468.1 [M+H]. Anal. Calcd for 
C21H20F3N3S3: C, 53.94; H, 4.31; N, 8.99. Found: C, 54.15; H, 4.46; N, 8.86. 
4.1.14 Benzo[d]thiazol-2-ylmethyl4-(4-(trifluoromethyl)benzyl) piperazine-1-
carbodithioate (49) 
Obtained in 56% yield as a white solid. Purification by co-precipitation from DCM/n-hexane. 
1H-NMR (CDCl3): 2.59 (bs, 4H, CH2-piperazine), 3.63 (s, 2H, CH2), 4.00 (bs, 2H, CH2-
piperazine), 4.42 (bs, 2H, CH2 piperazine), 5.15 (s, 2H, CH2), 7.39-7.42 (m, 1H, H-aromatic), 
7.48-7.51 (m, 3H, H-aromatic), 7.62-7.64 (m, 2H, H-aromatic), 7.85-7.87 (m, 1H, H-aromatic), 
8.01-8.03 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 39.0 (CH2), 52.4 (CH2), 61.8 (CH2), 
121.6, 122.9, 125.2, 125.4 (m), 126.1, 128.4 (CH, q, J= 130 Hz, C-aromatic), 131.8 (m), 135.7, 
152.7, 161.2, 163.2, 167.7, 194.4 (C). 19F-NMR (CDCl3) δ: -63.00 (s, 3F). Melting point: 99-
101°C. UPLC-MS (Method C): Rt 2.03 min, MS [ESI, m/z]: 468.1 [M+H]. Anal. Calcd for 
C21H20F3N3S3: C, 53.94; H, 4.31; N, 8.99. Found: C, 53.77; H, 4.57; N, 8.83. 
4.1.15 Benzo[d]thiazol-2-ylmethyl4-phenethylpiperazine-1-carbodithioate (50) 
Obtained in 41% yield as a white solid. Purification by co-precipitation from DCM/n-hexane. 
1H-NMR (CDCl3): 2.62-2.70 (m, 6H, CH2), 2.85-2.82 (m, 2H, CH2), 4.01 (bs, 2H, CH2-
piperazine), 4.42 (bs, 2H, CH2-piperazine), 5.15 (s, 2H, CH2), 7.21-7.25 (m, 3H, H-aromatic), 
7.29-7.34 (m, 2H, H-aromatic), 7.37-7.41 (m, 1H, H-aromatic), 7.47-7.50 (m, 1H, H-aromatic), 
7.84-7.86 (m, 1H, H-aromatic), 8.00-8.02 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 33.1 
(CH2), 39.0 (CH2), 52.4 (CH2), 59.6 (CH2), 121.6, 122.9, 125.2, 126.0, 126.4, 128.5, 128.6 
(CH, C-aromatic), 135.7, 139.2, 152.7, 167.6, 194.5 (C). Melting point: 87-89°C. UPLC-MS 
(Method C): Rt 1.70 min, MS [ESI, m/z]: 414.2 [M+H]. Anal. Calcd for C21H23N3S3: C, 60.98; 
H, 5.61; N, 10.16. Found: C, 60.75; H, 5.42; N, 10.28. 
4.1.16 Benzo[d]thiazol-2-ylmethyl 4-(phenylsulfonyl)piperazine-1-carbodithioate (51) 
Obtained in 40% yield as a white solid. The crude product precipitated out from the reaction 
mixture. Purification by co-precipitation from DCM/n-hexane followed by flash column 
chromatography (DCM 100:0 v/v). 1H-NMR (CDCl3): 3.14-3.18 (m, 4H, CH2-piperazine), 
4.27 (bs, 4H, CH2-piperazine), 5.05 (s, 2H, CH2), 7.37-7.40 (m, 1H, H-aromatic), 7.45-7.49 
(m, 1H, H-aromatic), 7.56-7.60 (m, 2H, H-aromatic), 7.64-7.68 (m, 1H, H-aromatic), 7.76-7.78 
(m, 2H, H-aromatic), 7.81-7.83 (m, 1H, H-aromatic), 7.97-7.99 (m, 1H, H-aromatic). 13C-NMR 
(CDCl3) δ: 39.0 (CH2), 45.5 (CH2), 121.6, 122.8, 125.4, 126.2, 127.7, 129.4, 133.4 (CH, C-
aromatic), 135.2, 135.5, 152.4, 166.9, 195.5 (C). Melting point: 171-173°C. UPLC-MS 
(Method C): Rt 2.03 min, MS [ESI, m/z]: 450.1 [M+H], 472.1 [M+Na]. Anal. Calcd for 
C21H23N3S3: C, 60.98; H, 5.61; N, 10.16. Found: C, 60.75; H, 5.42; N, 10.28. 
4.1.17 Benzo[d]thiazol-2-ylmethyl4-benzoylpiperazine-1-carbodithioate (52) 
Obtained in 50% yield as a white solid. Purification by flash column chromatography (n-
hexane-EtOAc 100:0 v/v, increasing to 60:40 v/v). 1H-NMR (CDCl3): 3.31-4.57 (m, 8H, CH2-
piperazine), 5.11 (s, 2H, CH2), 7.36-7.39 (m, 1H, H-aromatic), 7.41-7.48 (m, 6H, H-aromatic), 
7.82-7.84 (m, 1H, H-aromatic), 7.98-8.00 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 38.9 
(CH2), 121.6, 122.9, 125.4, 126.2, 127.1, 128.7, 130.3 (CH), 134.7, 135.5, 152.5, 167.3, 170.7, 
195.4 (C). Melting point: 125-127°C. UPLC-MS (Method C): Rt 1.93 min, MS [ESI, m/z]: 
414.2 [M+H], 436.2 [M+Na]. Anal. Calcd for C20H19N3OS3: C, 58.08; H, 4.63; N, 10.16. 
Found: C, 57.91; H, 4.51; N, 10.38. 
4.1.18 Benzo[d]thiazol-2-ylmethyl4-phenylpiperazine-1-carbodithioate (53) 
Obtained in 48% yield as a white solid. Purification by co-precipitation from DCM/n-hexane. 
1H-NMR (CDCl3): 3.30 (bs, 4H, CH2-piperazine), 4.13 (bs, 2H, CH2-piperazine), 4.51 (bs, 2H, 
CH2-piperazine) 5.14 (s, 2H, CH2), 6.91-6.94 (m, 3H, H-aromatic), 7.27-7.32 (m, 2H, H-
aromatic), 7.35-7.39 (m, 1H, H-aromatic), 7.44-7.48 (m, 1H, H-aromatic), 7.82-7.84 (m, 1H, 
H-aromatic), 7.99-8.00 (m, 1H, H-aromatic). 13C-NMR (CDCl3) δ: 38.9 (CH2), 48.9 (CH2), 
116.4, 120.8, 121.6, 122.9, 125.3, 126.1, 128.45 (CH, C-aromatic), 135.7, 149.9, 152.6, 167.5, 
194.7 (C). Melting point: 110-112°C. UPLC-MS (Method C): Rt 2.18 min, MS [ESI, m/z]: 
386.2 [M+H]. Anal. Calcd for C19H19N3S3: C, 59.19; H, 4.97; N, 10.90. Found: C, 59.34; H, 
5.05; N, 10.75. 
 
4.2 Molecular modelling  
All molecular docking studies were performed on a Viglen Genie Intel®CoreTM i7-3770 vPro 
CPU@ 3.40 GHz x 8 running Ubuntu 18.04. Molecular Operating Environment (MOE) 
2019.1039 and Maestro (Schrödinger Release 2019-3)35 were used as molecular modelling 
software. The ZBD of M2-1 protein was downloaded from the PDB data bank 
(http://www.rcsb.org/; PDB code 6G0Y).20 The protein was pre-processed using the 
Schrödinger Protein Preparation Wizard by assigning bond orders, adding hydrogens and 
performing a restrained energy minimisation of the added hydrogens using the OPLS_2005 
force field. Ligand structures were built with MOE and then prepared using the Maestro 
LigPrep tool by energy minimising the structures (OPLS_2005 force filed), generating possible 
ionization states at pH 7±2, generating tautomers and low-energy ring conformers. A 12 Å 
docking grid (inner-box 10 Å and outer-box 21 Å) was prepared using as centroid the co-
crystallised Zn atom. Molecular docking studies were performed using Glide SP precision 
keeping the default parameters and setting 5 as number of output poses per input ligand to 
include in the solution. The output poses were saved as mol2 file. The docking results were 
visually inspected for their ability to bind the active site.  
Molecular dynamics simulations were performed on Viglen Genie Intel®Xeon® CPU ES-
2403 @ 1.80 GHz x 8 (graphic card: GeForce GTX 1080 Ti) running Ubuntu 18.04, using the 
Desmond package for MD simulation: OPLS_2005 force field in explicit solvent, employing 
the TIP3 water model. The initial coordinates for the MD simulation were taken from the best 
docking experiment result for each single compound. A cubic water box was used for the 
solvation of the system, ensuring a buffer distance of approximately 8 Å between each box side 
and the complex atoms. The system was neutralized adding 27 chlorine counter ions. The 
system was minimised and pre-equilibrated using the default relaxation routine implemented 
in Desmond. A 150 ns MD simulation was performed, during which the equation of motion 
were integrated using a 2 fs time step in the NPT ensemble, with temperature (300 K) and 
pressure (1 atm) constant. All other parameters were set using the Desmond default values. 
Data were collected every 10 ps (energy) and every 40 ps (trajectory). Each protein-ligand 
complex simulation was performed in triplicate, using every time a random seed as starting 
point. Visualisation of protein-ligand complex and MD trajectory analysis were carried out 
using Maestro. RMSD, secondary structure and protein-ligand interactions analyses were 
performed using the Simulation Event Analysis tool and the Simulation Interaction Diagram 
of Desmond. The ∆Gbinding values of the protein-ligand complex were calculated using the 
MM/GBSA method as implemented in the Prime module from Maestro using the default 
settings and the Maestro script termal_mmgbsa.py. Briefly, the script takes in the MD 
trajectory from the last 80 ns of simulation, splits it into individual frame snapshots (extracted 
every 0.400 ns, for a total of 201 frames), and runs each one through MMGBSA (after deleting 
waters and separating the ligand from the receptor). For each single simulation, an average 
∆Gbinding values for the 80 ns is calculated.  
 
4.3 Biological assays 
4.3.1 Media, cells, virus and compounds 
DMEM (catalogue no. 41965-039), PBS (catalogue no. 14190-094) and non-essential amino 
acid solution (NEAA; catalogue no. 11140-035) were obtained from Thermo Fisher Scientific. 
FBS was obtained from Hyclone (catalogue no. SV30160.03) and heat inactivated at 56°C for 
30min. HEp-2 cells, RSV-A Long strain and RSV-B Wash strain were obtained from ATCC. 
ALS-8112 was synthesized according to published procedures (purity >98%).40 
4.3.2 Virus and cells for in vitro standard antiviral assay 
HEp2 cells were seeded at 5x103 cells/well in a 96-well plate and were further cultured in 
DMEM (supplemented with 2% FBS and 1% NEAA) at 37°C and 5% CO2. The day after, 
medium was replaced by a serial dilution (1:2) of the antiviral test compounds in the same 
medium and the cultures were infected with RSV-A Long strain or RVS-B wash strain at an 
moi of 0.01 CCID50/cell (where CCID50 represents the 50% cell culture infectious dose in 
HEp2 cells). After 5 days, the typical cytopathic effect (CPE) was scored microscopically in 
all wells, on a scale of 0–5. The EC50 was calculated by logarithmic interpolation as the 
concentration of compound that resulted in a 50% protective effect against virus-induced CPE. 
Potential compound toxicity was evaluated in a similar set-up in treated, uninfected cultures 
where metabolic activity was quantified at day 5 by using the 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) readout. The CC50 was 
calculated by logarithmic interpolation as the concentration of compound that resulted in a 50% 
decrease in the MTS signal. 
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Appendix A. Supplementary data 
All experimental procedures and compound characterisation data for the reaction intermediates 
are reported and described in detail in the Supporting Information. 
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